Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Omeros Corporation is a biotechnology business based in the US. Omeros Corporation shares (OMER) are listed on the NASDAQ and all prices are listed in US Dollars. Omeros Corporation employs 213 staff and has a trailing 12-month revenue of around $90.5 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $3.32 |
|---|---|
| 52-week range | $1.86 - $14.61 |
| 50-day moving average | $4.88 |
| 200-day moving average | $5.01 |
| Wall St. target price | $20.00 |
| PE ratio | 1.115 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $3.14 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.32 from 2022-09-27
| 1 week (2022-09-21) | -15.52% |
|---|---|
| 1 month (2022-08-26) | -13.09% |
| 3 months (2022-06-28) | 12.16% |
| 6 months (2022-03-24) | -46.10% |
| 1 year (2021-09-28) | -75.92% |
|---|---|
| 2 years (2020-09-28) | -66.63% |
| 3 years (2019-09-27) | 16.4 |
| 5 years (2017-09-28) | 21.05 |
Valuing Omeros Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Omeros Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Omeros Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Omeros Corporation shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $90.5 million |
|---|---|
| Gross profit TTM | $-71,397,000 |
| Return on assets TTM | -39.51% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | $0.38 |
| Market capitalisation | $219.6 million |
TTM: trailing 12 months
We're not expecting Omeros Corporation to pay a dividend over the next 12 months.
Omeros Corporation's shares were split on 1 October 2009.
Over the last 12 months, Omeros Corporation's shares have ranged in value from as little as $1.86 up to $14.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Omeros Corporation's is 1.1782. This would suggest that Omeros Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR" (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington. .
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.